Press release
Global Primary Sclerosing Cholangitis Market Industry Outlook to 2026 With Acorda Therapeutics, Inc. (US), Gilead Sciences, Inc. (US), NGM Biopharmaceuticals (US), Intercept Pharmaceuticals & Others
Ask For Complimentary Sample PDF | Request At https://databridgemarketresearch.com/request-a-sample/?dbmr=global-primary-sclerosing-cholangitis-market
This Primary Sclerosing Cholangitis market report is a total overview of the market that covers various aspects of product definition, market segmentation based on various parameters, and the existing vendor landscape. This market research report is a scrupulous analysis of current scenario of the market, which covers several market dynamics. This report motivates clients to seek new business ventures and evolve better. This Primary Sclerosing Cholangitis market study also estimates the market status, market share, growth rate, sales volume, future trends, market drivers, market restraints, revenue generation, opportunities and challenges, risks and entry barriers, sales channels, and distributors.
This Primary Sclerosing Cholangitis market research report identifies and analyses the up-and-coming trends along with major drivers, restraints, challenges and opportunities in the market for pharmaceutical industry. This market research report deals with an array of important market related aspects which can be listed as follows; market size estimations, company and market best practices, entry level strategies, market dynamics, positioning, segmentations, competitive landscaping and benchmarking, opportunity analysis, economic forecasting, industry-specific technology solutions, roadmap analysis, and in-depth benchmarking of vendor offerings. Primary Sclerosing Cholangitis is the most appropriate, realistic and admirable market research report delivered with a supreme devotion and comprehension of business needs.
Key Market Competitors:
Few of the major competitors currently working in the primary sclerosing cholangitis market are Acorda Therapeutics, Inc. (US), Gilead Sciences, Inc. (US), NGM Biopharmaceuticals (US), Intercept Pharmaceuticals, Inc. (US), Dr. Falk Pharma GmbH (Germany), ALLERGAN (Ireland), Takeda Pharmaceutical Company Limited. (Japan), DURECT CORPORATION (US), Conatus Pharmaceuticals, Inc. (US), Sirnaomics, Inc. (US), and HighTide Therapeutics Inc. (China), Glenmark (India), Impax Laboratories, LLC (US), Mylan N.V. (US), Teva Pharmaceuticals Industries Ltd. (Israel) and few among others.
Market Drivers
Rise in incidence and prevalence rate of liver failure and bile cancer associated with PSC.
Large No. of pipeline molecules is expected to drive the growth of the market.
Market Restraints
Withdrawal of novel molecules from late stage clinical trials will restrain the growth of the market.
Organ transplantation remains the alternative which is associated with many risk factors like relapse of the disease.
Lack of skilled expertise in remote areas
Fewer Government initiatives taken in this direction.
Table of Contents
Introduction
1.Market Segmentation
2.Market Overview
3.Executive Summary
4.Premium Insights
5.Global, By Component
6.Product Type
7.Delivery
8.Industry Type
9.Geography
Get detailed toc @ https://databridgemarketresearch.com/toc/?dbmr=global-primary-sclerosing-cholangitis-market
Segmentation:
By Type
Classic PSC
Small-duct PSC
PSC associated with autoimmune hepatitis
By Treatment Type
Ursodeoxycholic acid
Obeticholic Acid
Methotrexate
Corticosteroids
Others
By Symptom Control
Antihistamines
Cholestyramine
Antibacterials
Opioid Antagonists
Colestipol
Others
By End- User
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Geography
North America
South America
Europe
Asia-Pacific
Middle East & Africa
Key Developments in the Market:
On 19th January, 2016, Acorda Therapeutics, Inc. announced that it entered into an agreement to acquire Biotie Therapies Corp. According to the agreement, the company will acquire the four pipeline products that include BTT1023, a fully human monoclonal antibody in Phase 2 development for treatment of primary sclerosing cholangitis (PSC) which will help company to grow.
On 27th March, 2019, Gilead Sciences, Inc. announced the company’s research and development programs in primary sclerosing cholangitis (PSC) will be presented at The International Liver Congress™ 2019 in Vienna. Currently the novel molecule, Cilofexor has not get the approval but once it gets approval it will generate the revenue for the company and contribute towards the growth of the market.
Competitive Analysis:
Global primary sclerosing cholangitis market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of primary sclerosing cholangitis market for global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.
Inquiry For Customize Report With Discount at : https://databridgemarketresearch.com/inquire-before-buying/?dbmr=global-primary-sclerosing-cholangitis-market
Contact:
Data Bridge Market Research
Tel: +1-888-387-2818
Email: Sopan.gedam@databridgemarketresearch.com
About Us:
Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.
Data bridge is an aftermath of sheer wisdom and experience which was formulated and framed in the year 2015 in Pune. We ponder into the heterogeneous markets in accord with our clients needs and scoop out the best possible solutions and detailed information about the market trends. Data Bridge delve into the markets across Asia, North America, South America, Africa to name few.
Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. We are content with our glorious 99.9 % client satisfying rate.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Global Primary Sclerosing Cholangitis Market Industry Outlook to 2026 With Acorda Therapeutics, Inc. (US), Gilead Sciences, Inc. (US), NGM Biopharmaceuticals (US), Intercept Pharmaceuticals & Others here
News-ID: 1791667 • Views: …
More Releases from Data Bridge Market Research
Water Treatment System Market: Sustaining the Future of Clean Water
Introduction
Understanding Water Treatment Systems
Water treatment systems are designed to purify and disinfect water for various uses-drinking, industrial processes, irrigation, and wastewater reuse. These systems eliminate contaminants such as bacteria, viruses, heavy metals, chemicals, and particulates, making water safe and sustainable for consumption and use.
Importance in Global Sustainability
Clean water is essential to life and industrial progress. With growing water demand and pollution, water treatment systems are now critical infrastructure across the…
Veterinary X-Ray Market Size, Analysis, Scope, Demand, Opportunities, Statistics
According to Data Bridge Market Research The global Veterinary X-Ray market size was valued at USD 915.19 million in 2024 and is projected to reach USD 1576.00 million by 2032, with a CAGR of 7.03 % during the forecast period of 2025 to 2032.
With increasing globalization and digital disruption, the Equine X-Ray Solutions Market is expanding across multiple industries, . Market research data indicates that businesses in the Companion Animal…
Veterinary X-Ray Market Size, Analysis, Scope, Demand, Opportunities, Statistics
According to Data Bridge Market Research The global Veterinary X-Ray market size was valued at USD 915.19 million in 2024 and is projected to reach USD 1576.00 million by 2032, with a CAGR of 7.03 % during the forecast period of 2025 to 2032.
With increasing globalization and digital disruption, the Equine X-Ray Solutions Market is expanding across multiple industries, . Market research data indicates that businesses in the Companion Animal…
Veterinary X-Ray Market Size, Analysis, Scope, Demand, Opportunities, Statistics
According to Data Bridge Market Research The global Veterinary X-Ray market size was valued at USD 915.19 million in 2024 and is projected to reach USD 1576.00 million by 2032, with a CAGR of 7.03 % during the forecast period of 2025 to 2032.
With increasing globalization and digital disruption, the Equine X-Ray Solutions Market is expanding across multiple industries, . Market research data indicates that businesses in the Companion Animal…
More Releases for Primary
Direct Primary Care Market
Direct Primary Care Market Worth 80.4 Bn 2031- Exclusive Report by InsightAce Analytic Pvt. Ltd.
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Direct Primary Care Market"- By Type (Clinical Services, Telehealth Services, Laboratory Services, Consultative Services), Care Setting (Office-Based DPC Practices, Home-Based DPC Practices, Telehealth-Only DPC Practices, Hybrid DPC Practices), End Users (Individuals, Employers, Small Businesses, Large Corporations, Insurance Companies (offering DPC as…
Primary Sclerosing Cholangitis Market
Primary Sclerosing Cholangitis (PSC) is a rare, chronic liver disease characterized by inflammation and scarring of the bile ducts, leading to liver damage and, ultimately, liver failure. The disease progresses slowly and often goes unnoticed in its early stages. Although the exact cause of PSC remains unknown, it is commonly associated with other inflammatory bowel diseases, particularly ulcerative colitis. The management of PSC includes symptom control, slowing disease progression, and…
Primary Biliary Cholangitis Treatment Market
Primary Biliary Cholangitis Treatment Market
Global Primary Biliary Cholangitis Treatment Market Expected to Reach US$ YY Million by 2030, Growing at a CAGR of YY%: Market Insights and Dynamics
The Global Primary Biliary Cholangitis Treatment Market, which reached US$ YY billion in 2022, is anticipated to achieve US$ YY million by 2030, exhibiting a robust CAGR of YY% during the forecast period from 2024 to 2031.
Primary Biliary Cholangitis (PBC), formerly known as…
Primary Healthcare Conference 2023
3rd World Congress on Primary Healthcare and Medicare Summit
Mercure Roma West, Viale degli Eroi di Cefalonia, 301, 00128 Rome, Italy
Email primaryhealthcare@pulsusgathering.org
On behalf of the Conference Organizing Committee, we would like to invite all of you for the "3rd Word Congress on Primary Healthcare and Medicare", which is going to be held in Rome, Italy on September 21-23, 2023. Primary Healthcare 2023 focuses on the basic theme "To Manifest the Multimorbidity…
Primary Lithium Battery (Primary Lithium Batteries) Market Key Companies and Ana …
The global lithium primary batteries market size will grow from $2.83 billion in 2022 to $2.9 billion in 2023 at a compound annual growth rate (CAGR) of 2.5%
Global " Primary Lithium Battery (Primary Lithium Batteries) Market" 2022 Reports give a Key study on the industry status of the Primary Lithium Battery (Primary Lithium Batteries) Manufacturer with the specific statistics, meaning, definition, SWOT Analysis, expert opinion, and recent development across…
Primary Prevention of Cancer
Primary prevention of cancer aims to prevent the disease before it ever occurs. More than 4 in 10 cancers as well as cancer deaths are linked to modifiable risk factors that can be altered as part of primary cancer prevention. The modifiable risk factors for primary prevention include:
1. Cigarette smoking: Smoking causes almost all cases of lung cancer and accounts for 30% of all cancer deaths. Prevention strategy for this risk…
